Cagrilintide
Long-acting amylin analogue
Related Laboratory Supplies
Essential items for laboratory research and sample preparation.
Third-Party Tested
HPLC Purity & Mass Spec Identity
Batch-Specific COA
Certificate for Each Batch
Discreet Packaging
Plain, Unbranded & Tamper-Evident
Same-Day Dispatch
Order Before 2PM AEST, Australia-Wide
Cagrilintide is a synthetic, long-acting amylin analogue studied for its activity at amylin receptors and its role in metabolic signalling. Research involving Cagrilintide examines pathways associated with appetite regulation, gastric motility and energy balance.
Cagrilintide Australia research material is intended for controlled laboratory investigations, including receptor activity and metabolic pathway studies. The material described here is supplied strictly for scientific research and is not intended for human or veterinary use.
What Is Cagrilintide?
Cagrilintide is a modified peptide analogue of amylin, a hormone naturally released alongside insulin by pancreatic beta cells. Amylin contributes to metabolic regulation through signalling pathways involved in satiety, gastric emptying and glucagon secretion.
Cagrilintide has been developed to provide prolonged amylin receptor activity compared with native amylin. Its molecular modifications include features designed to improve stability and extend its pharmacological activity.
Researchers investigate Cagrilintide to understand amylin receptor signalling, metabolic responses and interactions between hormonal pathways.
The Cagrilintide research peptide described on this page is separate from any pharmaceutical formulation being evaluated in clinical studies. Its identity, purity and other material characteristics must be established through product-specific analytical documentation.
Cagrilintide in Metabolic Research
Cagrilintide is investigated in several areas of metabolic science, particularly those involving amylin-mediated signalling.
Research topics include appetite-related signalling, gastric motility, energy balance and interactions between metabolic hormones.
Cellular studies can examine receptor activation, intracellular signalling and differences in responses between amylin receptor subtypes. Preclinical models provide additional information about physiological pathways.
Published clinical research has also investigated Cagrilintide, including its combination with semaglutide. Findings from pharmaceutical clinical studies should not be attributed to independently supplied laboratory material.
Quick Product Information
| Specification | Details |
|---|---|
| Product name | Cagrilintide |
| Research classification | Long-acting synthetic amylin analogue |
| Research targets | Amylin receptors (AMY1, AMY2 and AMY3) |
| Molecular formula | C₁₉₄H₃₁₂N₅₄O₅₉S₂ |
| Molecular weight | Approximately 4,409 g/mol |
| CAS number | 1415456-99-3 |
| Physical form | Lyophilised powder, subject to product specification |
| Available strengths | 5mg and 10mg |
| Purity | Refer to verified batch-specific CoA |
| Analytical testing methods | HPLC and MS or LC-MS, where documented |
| Certificate of Analysis | Batch-specific documentation, where available |
| Storage requirements | Follow verified product-specific storage instructions |
| Intended use | Laboratory and in-vitro research only |
How Cagrilintide Works in Research
Amylin Receptor Activity
Cagrilintide acts through amylin receptors, which are formed from a calcitonin receptor combined with receptor activity-modifying proteins (RAMPs).
These receptor complexes participate in signalling associated with food intake, gastric function and metabolic regulation. Their activity can be investigated using receptor-binding assays, cellular models and other controlled experimental systems.
Cellular Signalling Pathways
Amylin receptor activation can influence intracellular signalling involving cyclic adenosine monophosphate (cAMP) and related downstream mechanisms.
Laboratory studies examine how receptor activation produces measurable cellular responses and how these responses differ across experimental models.
Cagrilintide’s prolonged pharmacological activity makes it relevant to investigations of receptor signalling over time. Experimental findings depend on the model, assay conditions and material characteristics.
Cagrilintide vs Other Metabolic Research Peptides
Cagrilintide differs from incretin-based research peptides because its principal activity involves amylin receptors rather than GLP-1 or GIP receptors.
| Compound | Primary receptor activity |
|---|---|
| Cagrilintide | Amylin receptors |
| Semaglutide | GLP-1 receptor |
| Tirzepatide | GIP + GLP-1 receptors |
| Retatrutide | GIP + GLP-1 + glucagon receptors |
These compounds are studied through different receptor pathways. Their signalling characteristics, molecular structures and experimental applications should be considered separately.
Cagrilintide Research in Australia
Australian laboratories working with Cagrilintide should maintain appropriate records of material identity, batch identification, analytical testing and handling conditions.
The Therapeutic Goods Administration (TGA) regulates therapeutic goods in Australia. Research-only labelling does not automatically exempt a product from applicable regulatory requirements.
Cagrilintide is distinct from registered medicines containing other metabolic compounds. Its investigational status and the regulatory position of independently supplied material must be assessed separately.
Researchers should also consider relevant institutional requirements, laboratory safety procedures and any applicable importation or supply restrictions.
Specifications
Certificate of Analysis
Quality, Purity and Batch Testing
Analytical testing helps establish the identity and composition of Cagrilintide research material.
High-Performance Liquid Chromatography (HPLC) is used to separate components and assess chromatographic purity. The resulting profile can identify additional peaks associated with impurities or related substances.
Mass Spectrometry (MS or LC-MS) provides molecular mass information that can support identity verification.
A batch-specific Certificate of Analysis (CoA) should connect reported results to an identifiable material batch.
Purity percentages, test methods and analytical findings should only be published when supported by verified documentation. Analytical purity does not establish sterility, biological safety or suitability for human use.
Storage & Handling
Storage and Laboratory Handling
Cagrilintide should be stored according to the conditions specified in its product documentation and applicable laboratory procedures.
Temperature changes, moisture exposure, light and damaged packaging may affect sample integrity, depending on the formulation.
Researchers should maintain clear sample identification, inspect vial integrity and follow contamination-control procedures.
Storage temperatures, expiry dates and stability after reconstitution should not be assumed without supporting product-specific data.
Research Use Only: For Research Use Only. Not for human or veterinary use. This material is intended strictly for laboratory and in-vitro research purposes and must not be consumed or administered.
Reconstitution calculator: Cagrilintide 5mg
Work out concentration and the volume to draw for each aliquot before you add diluent.
- Concentration
- –
- Volume per aliquot
- –
- On a 1 mL (U-100) syringe
- –
- Aliquots per vial
- –
A laboratory arithmetic aid only. Verify every calculation independently. Not dosing guidance; research use only.
Cagrilintide Frequently Asked Questions
Cagrilintide is a synthetic, long-acting amylin analogue. It is investigated for its interaction with amylin receptors and signalling pathways involved in metabolic regulation.
Cagrilintide is a modified amylin peptide analogue. Its structure includes amino acid substitutions and lipid modification designed to extend its pharmacological activity compared with native amylin.
Cagrilintide activates amylin receptor complexes, including AMY1, AMY2 and AMY3. It also exhibits calcitonin receptor activity, making receptor selectivity an important subject of pharmacological research.
Cagrilintide primarily targets amylin receptor pathways, whereas Semaglutide activates GLP-1 receptors. These compounds have different molecular structures and signalling mechanisms, although both are investigated in metabolic research.
Cagrilintide is an amylin analogue, while Tirzepatide is a dual GIP and GLP-1 receptor agonist. Their receptor targets differ, leading researchers to investigate distinct metabolic signalling mechanisms.
Researchers study Cagrilintide to understand amylin-related signalling, appetite regulation, gastric function and energy balance. Laboratory models help investigate receptor responses and associated cellular mechanisms.
The molecular formula of Cagrilintide is C₁₉₄H₃₁₂N₅₄O₅₉S₂, with an approximate molecular weight of 4,409 g/mol. These identifiers describe the defined peptide molecule.
HPLC can assess chromatographic purity by separating components within a sample. Mass spectrometry supports molecular identity verification. Reported purity should correspond to an identifiable batch.
A CoA should identify the material, batch number, analytical methods, test results and relevant specifications. It should also provide sufficient documentation to support traceability.
No. This material is intended exclusively for laboratory and in-vitro research. It is not a registered therapeutic product and must not be consumed or administered to humans or animals.
No. This product is supplied strictly for in-vitro laboratory research. It is not approved for human or veterinary use and must not be consumed or administered.
Orders placed before 2PM AEST on business days are dispatched the same day from Melbourne. Standard Post takes 3–7 business days and Express Post 1–3 business days, both tracked and discreet.



Reviews
There are no reviews yet.